All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Telomeres are specialized structures that adorn the ends of eukaryotic chromosomes. Human telomeres comprise short tandem repeats 5'-TTAGGG-3' and telomere related proteins \[[@pone.0133174.ref001]\]. It is generally believed that telomeres protect chromosomes from degradation and end-to-end fusion, thus playing an essential role in maintaining chromosomal integrity \[[@pone.0133174.ref002]\]. In normal human somatic cells, telomeres ranges from 9 to 15 kb initially, and shrink by about 50--200 nucleotides per replication cycle \[[@pone.0133174.ref003]\]. With continuous shortening, telomeres reach a critical length and consequently the deficient telomere triggers irreversible cell cycle arrest known as cellular senescence, apoptosis and even malignance \[[@pone.0133174.ref004]\].

Telomere structure is sensitive to a wide spectrum of endogenous and environmental factors such as aging, oxidative stress, unhealthy lifestyle and genotoxic stress \[[@pone.0133174.ref005]\]. These factors jointly influence the cell fate jointly by modifying telomere length (TL) and structure and leading to disease occurrence. Therefore, TL has been proposed as an integrated biomarker for age and a general risk for age-associated diseases \[[@pone.0133174.ref006]\]. In particular, it has been reported that in mice models excessive telomere shortening contributes to the evolution of genome instability and thus is involved in cancer formation \[[@pone.0133174.ref007]--[@pone.0133174.ref009]\]. Accordingly, telomeres in human tumor cells were usually shorter than those in the surrounding normal tissue cells \[[@pone.0133174.ref010], [@pone.0133174.ref011]\].

Several studies have explored the correlations between TL and the risk of different cancers. Moreover, systematic reviews and meta-analyses have confirmed inverse associations of TL with cancer morbidity and other aging-related diseases \[[@pone.0133174.ref012]--[@pone.0133174.ref015]\]. There are also some prospective studies which examined the impact of TL on cancer survival, but the results are conflicting. For example, a recent report indicated that patients with shorter leukocyte TL had significantly worse overall survival and relapse-free survival than those with longer TL in colorectal cancer \[[@pone.0133174.ref016]\]. Conversely, Garcia-Aranda et al. found that long TL predicted poor colorectal cancer prognosis \[[@pone.0133174.ref017]\]. Svenson et al. showed that longer TL was associated with increased breast cancer death risk \[[@pone.0133174.ref018]\], while some other studies failed to observe a significant association \[[@pone.0133174.ref019]--[@pone.0133174.ref021]\]. These apparent discrepancies suggest that individual studies may be under powered for the detection of true associations due to limited sample sizes. Given this reason, we conducted a meta-analysis to provide a comprehensive assessment of the relationship between TL and cancer death and disease progression.

Methods {#sec006}
=======

Search strategy {#sec007}
---------------

We performed a systematic literature search on PubMed electronic database using the following key words: "telomere length", "cancer" or "carcinoma" or "tumor", and "survival" or "prognosis" or "mortality". The last search was updated on May 25, 2015. To identify more pertinent publications, the reference lists of selected articles were also hand searched.

Study selection {#sec008}
---------------

Studies which met the following criteria were eligible: (1). Study evaluated the relationship between TL and cancer survival with a prospective design. (2). Using long (or longest) TL as reference, the study provided relative risks (RRs) or hazard ratios (HRs) with 95% confidence intervals (CIs) for shorter (or shortest) TL. Alternatively, sufficient information was available to estimate the above effect sizes. (3). Participants must be newly diagnosed cancer patients. Therefore, studies focused on cancer-specific mortality in general population were excluded. (4). Studies analyzing the associations of TL with all-cause mortality were rejected because we were focused on cancer survival. If the same study was reported more than once, we selected the most recently published one to avoid repetition. In addition, if an article presented results for several different cohort studies we considered them as independent studies. There were no restrictions on cancer type, DNA source or measurement of TL.

Data extraction {#sec009}
---------------

For each eligible study, we used a standardized abstraction form to extract the following information: first author, year of publication, mean or middle point of follow-up time, region, cancer type, number of participants, measurement method for TL, DNA source, whether adjusted for age, TL classification (dichotomy, trichotomy or quartile), endpoint (death or disease progression), RRs or HRs with corresponding 95% CIs for short TL versus long TL, and adjusted confounders. If possible, the effect size with the largest degree of adjustment for potential confounders was included.

Quality assessment {#sec010}
------------------

The Newcastle Ottawa Scale (NOS) was used to assess the quality of the included studies \[[@pone.0133174.ref022]\]. Briefly, each study was judged on three broad dimensions: the selection of the study subjects, the comparability of the study populations and the ascertainment of the outcome of interest in cohort studies. Overall, each study received a total score from zero to nine stars, and a study was considered of high quality if it scored seven or more stars.

Statistical analysis {#sec011}
--------------------

To enrich our work, we not only analyzed the association of TL with cancer overall survival, but also extended the outcomes to cancer progression events, including treatment-free survival, relapse-free survival, disease-free survival and progression-free survival. For the vast majority of the studies included in this meta-analysis, a median value (or other cut-point) of the TL in cancer patients divided all subjects into two groups: a short TL group and a long TL group. The association between the TL and cancer survival was examined by RRs or HRs and corresponding 95% CIs with the long telomere as the reference. However, a few studies reported associations for tertile or quartile categories of TL. In these cases, we chose the effect size for shortest telomere versus longest telomere, with the group of longest telomere as the reference. Finally, we combined HRs with RRs and reported RRs as summary effect sizes for simplicity.

The between-study heterogeneity was assessed by the Cochran *Q* test and *I* ^*2*^ statistic and was considered significant if *P* \< 0.05 for Cochran *Q* test or *I* ^*2*^ \> 50%. When significant heterogeneity was detected, values from different studies were combined using a random-effects model; otherwise, a fixed-effects model was utilized. To evaluate the effect of TL on survival in patients with different cancer types, we detected this relationship by cancer type independently if it was reported in at last two studies. Meta-regression was performed to find the source of heterogeneity. Firstly, an empty regression was run to estimate the baseline value for *tau* ^*2*^. Then, univariate metaregressions were successively conducted with grouping variables. If *tau* ^*2*^ was significantly reduced after one variable entered into the model, then this variable was responsible for heterogeneity among the studies. In subgroup analysis, the included studies were stratified by the following items: age of diagnosis, follow-up time, area, cancer category, whether adjusted for age, number of subjects, technique for TL determination, DNA source, number of divided TL groups and risk type. Sensitivity analyses were performed by excluding each study individually and recalculating the pooled effect sizes. Additionally, we investigated publication bias by funnel plot and Egger's regression tests.

All analyses were conducted using Stata 10.0. All *P* values were two-sided and a *P* \< 0.05 was considered statistically significant.

Results {#sec012}
=======

Characteristics of included studies {#sec013}
-----------------------------------

As shown in [Fig 1](#pone.0133174.g001){ref-type="fig"}, the literature search strategy initially identified 739 articles. After scanning the titles and abstracts, sixty-nine publications remained for further investigation. Among these articles, thirty-six were excluded due to the following reasons: normal population as subjects but not cancer patients (n = 5), study on other diseases or disease therapy (n = 4), concerned with TL change or other intermediate phenotypes (n = 17), data not available for survival analysis (n = 9), or duplicated studies (n = 1). There were ten publications which researched both overall survival and disease progression, and one publication collected the results of two independent cohorts, thus they were considered separately. Finally, thirty-three articles containing forty-five independent studies were enrolled in our meta-analysis, of which twenty-seven studies were about cancer overall survival and eighteen studies were about cancer progression \[[@pone.0133174.ref016]--[@pone.0133174.ref021], [@pone.0133174.ref023]--[@pone.0133174.ref049]\]. The essential information for the included studies is listed in [Table 1](#pone.0133174.t001){ref-type="table"} and [S1 Table](#pone.0133174.s002){ref-type="supplementary-material"}. Diverse cancers were involved, including chronic lymphocytic leukemia, breast cancer, colorectal cancer, bladder cancer and many others. However, because there were too many cancer types, we combined these cancers into several major categories, including gastrointestinal cancer, female cancer, urinary cancer, neurological cancer, blood cancer and others, in meta-regression and subgroup analysis. The sources of DNA included blood (n = 21), tumor tissue (n = 18), mixed (n = 1) and unclear (n = 1). Quantitative polymerase chain reaction (qPCR) was the primary method for TL determination, while southern blot and fluorescence in situ hybridization-based (FISH) approaches were also utilized. Additionally, European was the predominant ethnic group reported, followed by American and Asian. Thirty-eight out of the forty-five included studies categorized TL into two groups: a long TL group and a short TL group. All the studies except one \[[@pone.0133174.ref044]\] were of high quality based on our NOS quality assessment.

10.1371/journal.pone.0133174.t001

###### Characteristics of included studies.

![](pone.0133174.t001){#pone.0133174.t001g}

  First author                                  Year   Cancer              Follow-up time[^a^](#t001fn001){ref-type="table-fn"}   Region    Method          Sample         TL groups   Risk (95% CI)
  --------------------------------------------- ------ ------------------- ------------------------------------------------------ --------- --------------- -------------- ----------- ---------------------
  Overall survival                                                                                                                                                                     
  Zhang                                         2014   ESCC                38 months                                              Asia      qPCR            tumor tissue   2           0.69 (0.46--1.02)
  Duggan                                        2014   breast cancer       11.2 years                                             America   qPCR            blood          2           1.32 (0.98--1.79)
  Chen                                          2014   colorectal cancer   28 months                                              Asia      qPCR            blood          2           2.43 (1.53--3.45)
  Russo                                         2014   bladder cancer      16.3 years                                             Europe    qPCR            blood          2           3.90 (1.70--9.10)
  Weischer                                      2013   multiple cancers    unclear                                                Europe    qPCR            blood          4           1.31 (1.14--1.52)
  Lötsch                                        2013   glioblastoma        14.2 months                                            Europe    qPCR            tumor tissue   2           0.93 (0.57--1.52)
  Mansouri                                      2013   CLL                 83 months                                              Europe    qPCR            blood          2           2.42 (1.40--4.19)
  Heaphy                                        2013   prostate cancer     13.2 years                                             America   FISH            tumor tissue   2           2.94 (1.35--6.39)
  Jeon                                          2014   NSCLC               unclear                                                Asia      qPCR            tumor tissue   4           2.43 (1.02--5.79)
  Liu                                           2012   HCC                 16.7 months                                            Asia      qPCR            blood          2           0.49 (0.35--0.68)
  Lu                                            2011   breast cancer       86 months                                              Europe    qPCR            tumor tissue   2           1.20 (0.71--2.04)
  Willeit                                       2011   multiple cancers    unclear                                                Europe    qPCR            blood          3           1.52 (1.05--2.21)
  Rossi                                         2009   CLL                 32 months                                              Europe    Southern blot   blood          2           13.31 (3.76--47.05)
  Rossi                                         2009   CLL                 54.2 months                                            Europe    Southern blot   blood          2           1.91 (1.04--3.52)
  Svenson                                       2009   ccRCC               24 months                                              Europe    qPCR            blood          2           0.33 (0.15--0.77)
  Svenson                                       2008   breast cancer       unclear                                                Europe    qPCR            blood          2           0.34 (0.16--0.75)
  Bechter                                       1998   CLL                 23 months                                              Europe    Southern blot   tumor tissue   4           3.27 (1.23--8.66)
  Kotsopoulos                                   2014   ovarian cancer      unclear                                                America   qPCR            blood          2           1.14 (0.91--1.30)
  Lin                                           2014   bladder cancer      21.6 months                                            America   qPCR            blood          2           1.25 (0.82--1.90)
  Shen                                          2012   breast cancer       8 years                                                America   qPCR            blood          2           0.87 (0.68--1.13)
  Hultdin                                       2003   CLL                 82 months                                              Europe    Southern blot   combined       2           2.00 (1.21--3.30)
  Gertler                                       2004   colorectal cancer   76 months                                              Europe    Southern blot   tumor tissue   2           3.56 (1.18--10.76)
  Gertler                                       2008   barrett carcinoma   79 months                                              Europe    Southern blot   tumor tissue   2           0.53 (0.34--0.84)
  Pezzolo                                       2015   NB tumors           43.2 months                                            Europe    FISH            tumor tissue   3           0.17 (0.05--0.53)
  Chen                                          2015   glioma              24 months                                              Asia      qPCR            blood          2           1.39 (1.04--1.86)
  Qu                                            2015   gastric cancer      42 months                                              Asia      qPCR            blood          2           2.78 (1.24--4.48)
  Boscolo-Rizzo                                 2015   HNSCC               24 months                                              Europe    qPCR            tumor tissue   2           1.20 (0.67--2.14)
  Disease/Progression/Treatment free survival                                                                                                                                          
  Spanoudakis                                   2011   MPN                 63 months                                              Europe    FISH            tumor tissue   2           0.48 (0.28--0.83)
  Chen                                          2014   colorectal cancer   28 months                                              Asia      qPCR            blood          2           2.26 (1.35--3.23)
  Mansouri                                      2013   CLL                 84 months                                              Europe    qPCR            blood          2           1.93 (1.16--3.19)
  Heaphy                                        2013   prostate cancer     13.2 years                                             America   FISH            tumor tissue   2           2.43 (1.24--4.76)
  Jeon                                          2014   NSCLC               unclear                                                Asia      qPCR            tumor tissue   4           1.56 (0.76--3.20)
  Lu                                            2011   breast cancer       86 months                                              Europe    qPCR            tumor tissue   2           1.20 (0.76--1.89)
  Rossi                                         2009   CLL                 32 months                                              Europe    Southern blot   blood          2           2.02 (1.33--3.07)
  Rossi                                         2009   CLL                 54.2 months                                            Europe    Southern blot   blood          2           2.14 (1.32--3.47)
  Rampazzo                                      2012   CLL                 45 months                                              Europe    qPCR            blood          2           2.97 (1.74--5.09)
  Borssén                                       2011   CLL                 58 months                                              Europe    qPCR            tumor tissue   2           0.36 (0.12--1.06)
  Yan                                           2013   AML                 12 months                                              Asia      Southern blot   tumor tissue   2           2.46 (1.38--4.38)
  Roos                                          2008   CLL                 52 moths                                               Europe    qPCR            unclear        2           1.47 (0.88--2.45)
  Garcia-Aranda                                 2006   colorectal cancer   43.8 months                                            Europe    Southern blot   tumor tissue   2           0.10 (0.01--0.74)
  Pezzolo                                       2015   NB tumors           43.2 months                                            Europe    FISH            tumor tissue   3           0.25 (0.10--0.63)
  Augustine                                     2015   colorectal cancer   21 months                                              America   qPCR            tumor tissue   2           1.82 (1.08--3.65)
  Chen                                          2015   glioma              24 months                                              Asia      qPCR            blood          2           1.41 (1.06--1.87)
  Qu                                            2015   gastric cancer      42 months                                              Asia      qPCR            blood          2           2.64 (1.19--4.55)
  Boscolo-Rizzo                                 2015   HNSCC               24 months                                              Europe    qPCR            tumor tissue   2           1.15 (0.59--2.25)

^a^: Mean or middle point of follow-up time.

Abbreviations: ESCC: esophageal squamous cell carcinoma, CLL: chronic lymphocytic leukemia, NSCLC: non-small-cell lung cancer, HCC: hepatocellular carcinoma, ccRCC: clear cell renal cell carcinoma, MPN: myeloproliferative neoplasms, AML: acute myelocytic leukemia, NB: neuroblastoma, HNSCC: head and neck squamous cell carcinoma, qPCR: quantitative polymerase chain reaction, FISH: fluorescence in situ hybridization-based approach.

![Flow chart for the process of selecting eligible articles.](pone.0133174.g001){#pone.0133174.g001}

Results of meta-analysis {#sec014}
------------------------

We observed consistent significant associations between TL and cancer overall survival and progression (Figs [2](#pone.0133174.g002){ref-type="fig"} and [3](#pone.0133174.g003){ref-type="fig"}). The combined risk for cancer overall survival was 1.30 (95% CI: 1.06--1.59) for short TL compared with long TL. However, these studies displayed high heterogeneity (*I* ^*2*^ = 83.5%, *P* = 0.012). Short TL was also associated with cancer progression risk: the pooled risk estimate was 1.44 (95% CI: 1.10--1.88), with significant heterogeneity (*I* ^*2*^ = 75.4%, *P* = 0.008). However, this association varied across different cancer types ([Fig 4](#pone.0133174.g004){ref-type="fig"}). Short TL predicted poor overall survival and cancer progression in chronic lymphocytic leukemia, the combined RRs were 2.68 (95%CI: 1.70--4.23, *P* = 0.000, *I* ^*2*^ = 52.9%) and 1.78 (95%CI: 1.25--2.54, *P* = 0.002, *I* ^*2*^ = 61.9%), respectively. Short telomeres were also associated with increased colorectal cancer mortality (RR = 2.54, 95%CI: 1.73--3.72, *P* = 0.000, *I* ^*2*^ = 0.0%) and decreased overall survival of esophageal cancer (RR = 0.61, 95%CI: 0.45--0.82, *P* = 0.001, *I* ^*2*^ = 0.0%). We failed to find significant associations in other cancers.

![Forest plot for association between telomere length and cancer overall survival.\
Results are presented for random effects models.](pone.0133174.g002){#pone.0133174.g002}

![Forest plot for association between telomere length and cancer progression.\
Disease-free survival, treatment-free survival, progression-free survival and relapse-free survival were involved. Results are presented for random effects models.](pone.0133174.g003){#pone.0133174.g003}

![The association between telomere length and cancer prognosis in different cancers.\
Only cancer types included at least two studies are presented.](pone.0133174.g004){#pone.0133174.g004}

Meta-regression and subgroup analyses {#sec015}
-------------------------------------

Meta-regression and subgroup analyses were performed to explore the potential source of between-study heterogeneities. No subgroup presented in our study could perfectly explain the heterogeneous results for overall cancer survival ([Table 2](#pone.0133174.t002){ref-type="table"}). However, when cancers were grouped into site-specific types, the results showed that short telomere was associated with increased death risk in blood cancer (RR = 2.68, 95%CI: 1.70--4.24, *P* = 0.000, *I* ^*2*^ = 52.9%), but not other cancer categories. We also found the relationship between TL and overall cancer survival was significant in studies with older subjects (RR = 1.83, 95%CI: 1.24--2.68, *P* = 0.002, *I* ^*2*^ = 70.1%), with full revisit (RR = 1.60, 95%CI: 1.11--2.30, *P* = 0.011, *I* ^*2*^ = 88.0%), with adjustment for age (RR = 1.39, 95%CI: 1.09--1.78, *P* = 0.008, *I* ^*2*^ = 76.6%), measuring TL using southern blot (RR = 2.34, 95%CI: 1.05--5.20, *P* = 0.038, *I* ^*2*^ = 86.9%), using blood samples (RR = 1.34, 95%CI: 1.05--1.70, *P* = 0.018, *I* ^*2*^ = 85.9%), dividing TL into two groups (RR = 1.30, 95%CI: 1.02--1.65, *P* = 0.035, *I* ^*2*^ = 84.6%) or four groups (RR = 1.88, 95%CI: 1.03--3.43, *P* = 0.040, *I* ^*2*^ = 91.7%) and estimating risk effects by HRs (RR = 1.43, 95%CI: 1.10--1.86, *P* = 0.008, *I* ^*2*^ = 84.9%). As for cancer progression, sample size may explain part of the heterogeneity, with *tau* ^*2*^ robustly reduced from 0.337 to 0.215 (*P* = 0.022) in a univariate meta-regression model. Additionally, *tau* ^*2*^ was reduced from 0.337 to 0.265 when stratified by risk type, suggesting that statistical method might also introduce heterogeneity (*P* = 0.050). Accordingly, only studies with larger sample size or reporting HRs remained significant after stratification, with RRs being 1.93 (95% CI: 1.58--2.36, *P* = 0.000, *I* ^*2*^ = 38.7%) and 1.69 (95% CI: 1.36--2.11, *P* = 0.000, *I* ^*2*^ = 60.1%), respectively ([Table 3](#pone.0133174.t003){ref-type="table"}). In addition, short telomere predicted poor outcomes in cancer progression in studies with older participants (RR = 1.86, 95%CI: 1.37--2.54, *P* = 0.000, *I* ^*2*^ = 51.1%), with Asian or American subjects (for Asian: RR = 1.90, 95%CI: 1.44--2.51, *P* = 0.000, *I* ^*2*^ = 37.6%; for American: RR = 2.07, 95%CI: 1.32--3.26, *P* = 0.002, *I* ^*2*^ = 0.0%), with adjustment for age (RR = 1.69, 95%CI: 1.38--2.08, *P* = 0.000, *I* ^*2*^ = 20.1%), measuring TL using southern blot or qPCR (for southern blot: RR = 1.79, 95%CI: 1.04--3.10, *P* = 0.037, *I* ^*2*^ = 67.8%; for qPCR: RR = 1.64, 95%CI: 1.30--2.07, *P* = 0.000, *I* ^*2*^ = 52.4%), using blood samples (RR = 2.01, 95%CI: 1.64--2.47, *P* = 0.000, *I* ^*2*^ = 31.1%) and dichotomizing TL (RR = 1.56, 95%CI: 1.21--2.02, *P* = 0.001, *I* ^*2*^ = 72.0%).

10.1371/journal.pone.0133174.t002

###### Subgroup analyses of telomere length and overall cancer survival.

![](pone.0133174.t002){#pone.0133174.t002g}

  Subgroup[^a^](#t002fn001){ref-type="table-fn"}   No. of studies   Risk (95% CI)        *P*     *I* ^*2*^   *P* for metareg
  ------------------------------------------------ ---------------- -------------------- ------- ----------- -----------------
  Age                                                                                                        0.323
   \< = 63 years                                   11               1.12 (0.74--1.69)    0.607   87.10%      
   \> 63 years                                     10               1.83 (1.24--2.68)    0.002   70.10%      
   Unclear                                         6                1.17 (0.90--1.52)    0.247   83.20%      
  Follow-up time                                                                                             0.585
   \< 48 months                                    12               1.18 (0.77--1.81)    0.458   88.00%      
   \> = 48 months                                  10               1.60 (1.11--2.30)    0.011   81.00%      
   Unclear                                         5                1.20 (0.91--1.58)    0.196   74.50%      
  Region                                                                                                     0.999
   Asia                                            6                1.35 (0.75--2.41)    0.317   91.20%      
   America                                         5                1.20 (0.95--1.52)    0.129   63.50%      
   Europe                                          16               1.31 (0.95--1.81)    0.098   82.70%      
  Cancer category                                                                                            0.177
   GCs                                             6                1.19 (0.61--2.34)    0.611   91.80%      
   Female cancers                                  5                1.00 (0.76--1.31)    0.990   70.20%      
   Urinary cancers                                 3                1.17 (0.37--3.72)    0.788   88.40%      
   NCs                                             3                0.76 (0.34--1.66)    0.484   83.90%      
   Blood cancers                                   5                2.68 (1.70--4.24)    0.000   52.90%      
  Whether adjusted for age                                                                                   0.728
   Yes                                             13               1.39 (1.09--1.78)    0.008   76.60%      
   No                                              14               1.24 (0.88--1.75)    0.225   87.00%      
  Number of participants                                                                                     0.947
   \< 250                                          14               1.34 (0.89--2.02)    0.156   83.70%      
   \> = 250                                        13               1.28 (1.01--1.62)    0.043   84.60%      
  Method                                                                                                     0.253
   qPCR                                            19               1.19 (0.98--1.46)    0.087   82.30%      
   FISH                                            2                0.73 (0.05--11.96)   0.827   93.60%      
   Southern blot                                   6                2.34 (1.05--5.20)    0.038   86.90%      
  DNA source                                                                                                 0.933
   Blood                                           16               1.34 (1.05--1.70)    0.018   85.90%      
   Tumor tissue                                    10               1.18 (0.76--1.83)    0.473   78.90%      
  TL groups                                                                                                  0.365
   2                                               22               1.30 (1.02--1.65)    0.035   84.60%      
   3                                               2                0.55 (0.06--4.68)    0.583   60.60%      
   4                                               3                1.88 (1.03--3.43)    0.040   91.70%      
  Risk type                                                                                                  0.423
   RR                                              10               1.12 (0.80--1.56)    0.525   81.00%      
   HR                                              17               1.43 (1.10--1.86)    0.008   84.90%      
  Total                                            27               1.30 (1.06--1.59)    0.012   83.50%      

^a^: present result if two or more studies included in a subgroup.

Abbreviations: GC: gastrointestinal cancer, NC: neurologic cancer.

10.1371/journal.pone.0133174.t003

###### Subgroup analysis of telomere length and cancer progression.

![](pone.0133174.t003){#pone.0133174.t003g}

  Subgroup[^a^](#t003fn001){ref-type="table-fn"}   No. of studies   Risk (95% CI)       *P*     *I* ^*2*^   *P* for metareg
  ------------------------------------------------ ---------------- ------------------- ------- ----------- -----------------
  Age                                                                                                       0.609
   \< = 60 years                                   8                1.27 (0.86--1.89)   0.223   74.90%      
   \> 60 years                                     8                1.86 (1.37--2.54)   0.000   51.10%      
   Unclear                                         2                1.05 (0.23--4.81)   0.951   94.70%      
  Follow-up time                                                                                            0.990
   \< 45 months                                    9                1.45 (0.99--2.13)   0.056   75.60%      
   \> = 45 months                                  8                1.40 (0.89--2.18)   0.146   80.40%      
  Region                                                                                                    0.256
   Asia                                            5                1.90 (1.44--2.51)   0.000   37.60%      
   America                                         2                2.07 (1.32--3.26)   0.002   0.00%       
   Europe                                          11               1.08 (0.70--1.66)   0.739   82.50%      
  Cancer type                                                                                               0.640
   GCs                                             4                1.71 (0.90--3.25)   0.104   69.40%      
   Blood cancers                                   8                1.51 (0.97--2.34)   0.066   80.80%      
   NCs                                             2                0.63 (0.12--3.41)   0.591   91.90%      
  Whether adjusted for age                                                                                  0.254
   Yes                                             7                1.69 (1.38--2.08)   0.000   20.10%      
   No                                              11               1.14 (0.71--1.82)   0.589   83.60%      
  Number of participants                                                                                    0.022
   \< 170                                          9                0.87 (0.51--1.50)   0.612   80.40%      
   \> = 170                                        9                1.93 (1.58--2.36)   0.000   38.70%      
  Method                                                                                                    0.210
   qPCR                                            11               1.64 (1.30--2.07)   0.000   52.40%      
   FISH                                            3                0.68 (0.19--2.40)   0.546   89.90%      
   Southern blot                                   4                1.79 (1.04--3.10)   0.037   67.80%      
  DNA source                                                                                                0.099
   Blood                                           7                2.01 (1.64--2.47)   0.000   31.10%      
   Tumor tissue                                    10               0.95 (0.58--1.57)   0.854   80.10%      
  TL groups                                                                                                 0.100
   2                                               16               1.56 (1.21--2.02)   0.001   72.00%      
  Risk type                                                                                                 0.050
   RR                                              4                0.55 (0.17--1.82)   0.330   87.60%      
   HR                                              14               1.69 (1.36--2.11)   0.000   60.10%      
  Total                                            18               1.44 (1.10--1.88)   0.008   75.40%      

^a^: results of subgroups with two or more studies included were presented.

Abbreviations: GC: gastrointestinal cancer, NC: neurologic cancer.

Sensitivity analysis and publication bias {#sec016}
-----------------------------------------

Sensitivity analysis was performed subsequently. However, removing each study individually did not alter the relationships between TL and cancer outcomes materially ([S2 Table](#pone.0133174.s003){ref-type="supplementary-material"}). The pooled RRs for overall survival range from 1.24 (95% CI: 1.02--1.52) to 1.36 (95% CI: 1.12--1.65), and cancer progression from 1.37 (95% CI: 1.05--1.81) to 1.57 (95% CI: 1.23--2.01), while both of the relevant between-study heterogeneities remained significant. A funnel plot was drawn for twenty-seven studies which focused on overall cancer survival, and results showed no obvious asymmetry ([Fig 5](#pone.0133174.g005){ref-type="fig"}). On the basis of Egger's regression test and Begg's test, there was no evidence of publication bias among these studies (*P* = 0.431 for Egger's test, *P* = 0.144 for Begg's test).

![Publication bias within cancer overall survival.](pone.0133174.g005){#pone.0133174.g005}

Discussion {#sec017}
==========

The present meta-analyses of thirty-three independent articles, involving up to 11429 cancer patients for overall survival and 4293 cancer patients for disease progression, identified significant inverse associations between TL and cancer survival outcomes. TL was an independent predictor of prognosis in chronic lymphocytic leukemia, but not in other cancers. This association appeared to be more obvious in older populations, though it was still significant when adjusted for age. As compared with other methods (qPCR and FISH), the application of southern blot resulted in a more robust association. It also seemed that TL in blood cells was a better cancer survival predictor than TL in tumor tissue cells. In addition, large sample sizes and appropriate statistical methods guaranteed a significant association.

Telomeres play a key role in maintenance of cellular senescence and homeostasis. Over the past decades, increasing numbers of studies have observed telomere dysfunction in cancer initiation and development. Telomerase appeared to be repressed in human normal somatic cells but reactivated in cancer cells \[[@pone.0133174.ref050], [@pone.0133174.ref051]\]. Elevated telomerase mRNA expression and telomerase activity in cancer patients both predicted a poor prognosis \[[@pone.0133174.ref052], [@pone.0133174.ref053]\]. In the last few years, several single nucleotide polymorphisms (SNPs) in telomere related key genes have been identified as associated with cancer susceptibility \[[@pone.0133174.ref054]--[@pone.0133174.ref059]\] and cancer survival \[[@pone.0133174.ref060]\]. Moreover, Codd et al. showed that SNPs involved in telomere biology were associated with not only mean leukocyte TL but also with risks of several cancers and aging-associated diseases \[[@pone.0133174.ref061]\]. A hypothesis was that excessive telomere shortening and serious telomere uncapping could trigger DNA damage responses at chromosome ends, which were then recognized as double-strand breaks. Whether dysfunctional telomeres led to cancer or not would depend on the integrity of DNA damage responses \[[@pone.0133174.ref062]\]. On the other hand, critical telomere shortening was supposed to constitute a driving force for cellular transformation by causing genome instability, thus contributing to tumorigenesis \[[@pone.0133174.ref063]\]. As an integrated indicator of endogenous and environmental damages, TL was inversely associated with cancer susceptibility based on relevant studies and systematic reviews. Our meta-analysis suggested that TL might serve as a useful cancer prognostic biomarker and a potential therapeutic target for cancer treatment. However, the underlying mechanisms need to be clarified.

Tumorigenesis and progression are complicated processes affected by various genetic and environmental factors \[[@pone.0133174.ref064]--[@pone.0133174.ref067]\]. Although the present study showed a significant association between short TL and poor cancer prognosis, we still need to draw conclusions with caution based on the stratification results. Short TL may predispose to a number of cancers, but in contrast to the common pattern, longer telomeres were associated with increased risk of certain cancers, such as melanoma \[[@pone.0133174.ref068], [@pone.0133174.ref069]\] and soft tissue sarcoma \[[@pone.0133174.ref070]\]. Similarly, we found short telomeres predicted poor prognosis in chronic lymphocytic leukemia and colorectal cancer, but reduced death risk in esophagus cancer. Intrinsic biological heterogeneities in different cancers may be a plausible explanation. Distinct biological pathways may be influenced quite differently by TL, resulting in diverse effects on survival of different cancers. However, the number of studies included for each cancer type was far from adequate. To obtain reliable results, more relevant studies are warranted. Age is by far the predominant predictor of individual TL, explaining an estimated 17.5% of the inter-individual variation in leukocyte TL \[[@pone.0133174.ref071]\]. It is worth considering that TL was significantly related to cancer prognosis in studies which adjusted for age, while no significant evidence was detected in studies without age adjustment. Apparently, not only age, but also many other factors jointly contributed to cancer development and progression. We observed that if a study adjusted for age, it usually adjusted for other confounders at the same time, such as gender, smoking, stage, histology and gene expression. However, the other studies made no adjustments. Therefore, we suspected that in studies without age adjustment, other essential confounders might bias the true association. In our meta-analyses, short TL predicted terrible cancer prognosis in patients with older mean age. However, this relationship disappeared in younger patients. Recently Jeon et al. reported a similar result: shorter TL was associated with a significantly poor overall survival and disease-free survival in cancer patients more than 63 years old but not in younger patients \[[@pone.0133174.ref036]\]. Moreover, Cawthon et al. found telomere shortening in blood contributed to mortality in people aged 60 years or older \[[@pone.0133174.ref072]\]. We speculated that aged patients were vulnerable and therefore might be more sensitive to fragile telomeres than younger patients. Nevertheless, opposite and indeterminate findings also exist \[[@pone.0133174.ref025], [@pone.0133174.ref033]\]. In Asian and American subjects, significant associations were found for cancer progression, but not for overall cancer survival, while TL was neither associated with overall survival nor with cancer progression in Europeans. Owing to the high heterogeneity within studies of European subjects, it is hard to draw the negative conclusion. Besides, ethnicity might differ from person to person, even if they came from the same country. However, we could not investigate this relationship because there was insufficient information.

Other factors including study design, experimental approach and analysis strategy can also influence the detection of the relationships between TL and cancers. As compared to qPCR, southern blot conferred a modestly stronger effect for both overall cancer survival and progression. Unlike direct measurement such as by southern blot, qPCR evaluate TL using a ratio of telomere/single copy gene (T/S) \[[@pone.0133174.ref073]\]. This indirect method can't generate absolute values for TL, and thus may introduce measurement error and bias real effects. TL in blood cells showed a stronger relationship with age compared with TL in other tissues, whether in healthy populations or in cancer patients \[[@pone.0133174.ref072], [@pone.0133174.ref074]\]. Our results were in agreement with this and suggested that leucocyte TL might be a preferential indicator for age-related disease and disease survival. This was exciting because blood is a convenient tissue to collect and yields high-quality DNA which is more suitable for TL assays than that from other tumor or non-tumor tissues. In the great majority of the included studies, telomeres were divided into two groups: a long telomere group and a short telomere group. Although the classification criteria might be different (e.g. median of TL, cut-point from ROC curve or empirical value), our results showed that dichotomizing TL was sufficient to find a significant association. However, association was non-significant in studies which divided telomeres into three groups. Since only two studies were in this subgroup, we think more studies are needed. In addition, studies with larger sample sizes and estimating risk effects using HRs explained part of the heterogeneity among studies for cancer progression and shared consistent significant associations for overall cancer survival and progression, indicating that well designed large cohort studies are necessary to discover the true associations.

As far as we are aware, this is the first meta-analysis discussing the association between TL and cancer survival. The included articles were all prospective studies, and the records of TL and disease outcomes were considered credible. Our results seemed stable and reliable after performing sensitivity analyses and testing the publication bias. Despite its strengths, some limitations should be acknowledged. Firstly, we failed to find definitive sources of heterogeneity in the studies for cancer overall survival. Discords existed in the results of several subgroups after stratification, for example, TL was significantly associated with cancer overall survival in studies with older mean age, but not in younger patients. However, these discrepancies cannot be the cause of the heterogeneity as there was high heterogeneity among the studies in each subgroup. Although we have identified a partial source of heterogeneity for cancer progression, we could not investigate further due to limited information. Secondly, TLs were measured at a single time point in our included studies. A series of longitudinal TL records might contribute to characterization of the dynamic variation of this association. Lastly, cancer survival was determined by many factors, including cancer stage, pathological pattern, and critically, disease therapy. Only discussing age in our stratification analyses could be considered insufficient. More large scale studies are required to further explore the association and uncover the underlying biological mechanism.

In conclusion, our meta-analyses provided evidence for an inverse association between TL and risk of cancer survival, particularly for chronic lymphocytic leukemia. The association suggested that leucocyte TL might be a predictive biomarker for cancer prognosis in old people. However, our findings need to be updated and confirmed in the future, and additional studies are required to further characterize the nature of this association under different circumstances.
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